|
International AIDS Education and Training Center |
E. Michael Reyes, MD, MPH |
Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Gabon, Egypt, Morocco, Sudan, Tunisia, Botswana, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Ivory Coast, Gambia, Ghana, Guinea-Bissau, Mali, Niger, Nigeria, Senegal, Togo, Kyrgyzstan, China, Bangladesh, India, Iran, Nepal, Pakistan, Sri Lanka, Cambodia, Indonesia, Viet Nam, Laos, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Georgia, Iraq, Lebanon, Yemen, Czech Republic, Estonia, Greece, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Venezuela, Antigua and Barbuda, Bahamas, Barbados, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Puerto Rico, Trinidad and Tobago, Australia |
|
|
|
Failure Time Methods for Family Disease Studies |
David Glidden, PhD |
United States, Australia |
|
|
|
San Francisco National Clinical Trial Center, ESPIRIT |
Steven Deeks, MD |
Morocco, Japan, Singapore, Thailand, Israel, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, United Kingdom, Argentina, Brazil, Canada, Australia |
|
|
|
WHO Adolescent HTC Review Update (PO# 200660799) |
George Rutherford, MD |
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Western Africa, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, Japan, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka, Brunei, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu |
|
|
|
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus |
Mandana Khalili, MD |
Mexico, Argentina, Puerto Rico, Australia |
|
|
|
Assess Clonidine and Aspirin in Noncardiac Surgery Patients at Risk of Perioperative Cardiovascular Event |
|
South Africa, China, India, Pakistan, Malaysia, Austria, Belgium, Denmark, France, Germany, Italy, Spain, Switzerland, United Kingdom, Argentina, Brazil, Chile, Colombia, Peru, Canada, Australia |
|
|
|
Women, Children, and HIV Website |
Susan Coffey, MD |
Kenya, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Botswana, Lesotho, Namibia, South Africa, Swaziland, Gambia, Ghana, Liberia, Nigeria, India, Pakistan, Sri Lanka, Singapore, Philippines, United Kingdom, Anguilla, Antigua and Barbuda, Bahamas, Barbados, Cayman Islands, Dominica, Grenada, Jamaica, Saint Kitts and Nevis, Saint Lucia, Trinidad and Tobago, U.S. Virgin Islands, Northern Mariana Islands, Australia, Marshall Islands, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu |
|
|
|
BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 |
Mandana Khalili, MD |
Egypt, Sweden, Mexico, Puerto Rico, Canada, Australia |
|
|
|
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV |
Anne Luetkemeyer, MD |
France, Germany, Italy, Russia, Spain, United Kingdom, Argentina, Puerto Rico, Canada, Australia |
|
|
|
International Collaborative of Prospective Studies of HIV and Hepatitis in IDU |
Kimberly Page, PhD, MPH |
Netherlands, Canada, Australia |
|
|
|
AIDS Malignancies Consortium |
Lawrence Kaplan, MD |
Kenya, Uganda, Zimbabwe, South Africa, India, Brazil, Australia |
|
|
|
Office of the UN Special Envoy for Tuberculosis |
Eric Goosby, MD |
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe, Angola, Cameroon, Central African Republic, Chad, Congo (Kinshasa), Congo (Brazzaville), Equatorial Guinea, Gabon, Sao Tome and Principe, Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara, Botswana, Lesotho, Namibia, South Africa, Swaziland, Benin, Burkina Faso, Cape Verde, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Central Asia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, China, Hong Kong S.A.R., China, North Korea, South Korea, Macao S.A.R., China, Mongolia, Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Singapore, Thailand, Timor-Leste, Philippines, Armenia, Azerbaijan, Bahrain, Cyprus, Georgia, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Palestinian Territory, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, Yemen, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Caribbean, Anguilla, Turks and Caicos Islands, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, Jamaica, Martinique, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Bermuda, Canada, Greenland, U.S. Virgin Islands, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu |
|
|
|
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) |
Ann Schwartz, PhD, MPH |
South Africa, India, Thailand, Belgium, Ireland, Italy, Spain, United Kingdom, Brazil, Peru, Australia |
|
|
|
VIPS: Vascular Effects of Infection in Pediatric Stroke |
Heather Fullerton, MD |
China, Malaysia, Argentina, Chile, Australia |
|
|
|
Development of Antimalarial Drug Leads Through Inhibition of Food Vacuole Falcipains |
Philip J. Rosenthal, MD |
Australia |
|
|
|
Fighting emerging antimalarial drug resistance |
Philip J. Rosenthal, MD |
Australia |
|
|
|
DARE: Delaney AIDS Research Enterprise to Find a Cure |
Steven Deeks, MD |
Sweden, Australia |
|
|
|
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial |
Nisha Acharya, MD |
India, Mexico, Australia |
|
|
|
Multicenter Uveitis Steroid Treatment (MUST) Trial |
Nisha Acharya, MD |
United Kingdom, Australia |
|
|
|
DFAT Vector Control Technical Landscape Analysis in the Indo-Pacific |
Allison J. Tatarsky, MPH |
China, Japan, Bangladesh, Bhutan, Sri Lanka, Brunei, Cambodia, Indonesia, Viet Nam, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Philippines, U.S. Virgin Islands, Oceania, American Samoa, Northern Mariana Islands, Australia, Cook Islands, Guam, French Polynesia, Fiji, Kiribati, Marshall Islands, Micronesia, Nauru, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu |
|
|
|
Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 |
Mandana Khalili, MD |
South Korea, Japan, India, Singapore, Belgium, Finland, France, Greece, Italy, Netherlands, Russia, United Kingdom, Mexico, Argentina, Brazil, Chile, Canada, Australia, New Zealand |
|
|
|
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START |
Richard Price, MD |
Uganda, Morocco, South Africa, Mali, Nigeria, China, Japan, India, Malaysia, Thailand, Israel, Mexico, Brazil, Chile, Peru, Uruguay, Australia |
|
|
|
Improving Medicines Use for Noncommunicable Diseases in Low Resource Settings |
Lisa Bero, PhD |
Australia |
|
|
|
Individual, social, and structural factors on disease transmission in marginalized populations |
Meghan Morris, PhD, MPH |
Tanzania, Namibia, Mexico, Jamaica, Australia |
|
|
|
AIDS Malignancy Consortium (AMC) |
Lawrence Kaplan, MD |
Kenya, Malawi, Uganda, Tanzania, Zimbabwe, South Africa, India, Brazil, Australia |
|
|